Isodiol International (Isodiol International) EBIT : $-68.86 Mil (TTM As of Dec. 2019)

View and export this data going back to 2014. Start your Free Trial

What is Isodiol International EBIT?

Isodiol International's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2019 was $-0.60 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2019 was $-68.86 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Isodiol International's annualized ROC % for the quarter that ended in Dec. 2019 was -79.05%. Isodiol International's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2019 was -160.59%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Isodiol International EBIT Historical Data

The historical data trend for Isodiol International's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Isodiol International EBIT Chart

Isodiol International Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

EBIT

Get a 7-Day Free Trial

-0.46

-6.50

-3.15

-27.62

-85.96

Isodiol International Quarterly Data
	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19
EBIT	Get a 7-Day Free Trial															-16.21	-63.82	-2.06	-2.38	-0.60

Competitive Comparison of Isodiol International's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Isodiol International's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Isodiol International's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Isodiol International's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Isodiol International's EV-to-EBIT falls into.

Isodiol International EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-68.86 Mil.

Isodiol International (OTCPK:ISOLF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Isodiol International's annualized ROC % for the quarter that ended in Dec. 2019 is calculated as:

	ROC % (Q: Dec. 2019 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2019 )	+	Invested Capital (Q: Dec. 2019 ))	/ count )
=	-4.184 * ( 1 - 0% )	/	( (5.403	+	5.183)	/ 2 )
=	-4.184	/	5.293
=	-79.05 %

where

	Invested Capital		(Q: Sep. 2019 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	11.076	-	4.487	-	( 1.186	-	max(0, 6.387	-	7.753	+	1.186	))
=	5.403

	Invested Capital		(Q: Dec. 2019 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	8.374	-	2.469	-	( 1.144	-	max(0, 4.379	-	5.101	+	1.144	))
=	5.183

Note: The Operating Income data used here is four times the quarterly (Dec. 2019) data.

2. Joel Greenblatt's definition of Return on Capital:

Isodiol International's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2019 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2019 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2019		Q: Dec. 2019
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-2.412	/	( ( (1.563 + max(-1.861, 0))	+	(1.441 + max(-1.427, 0)) )	/	2 )
=	-2.412	/	( ( 1.563	+	1.441 )	/	2 )
=	-2.412	/	1.502
=	-160.59 %

where Working Capital is:

	Working Capital		(Q: Sep. 2019 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.702	+	0.791	+	1.905)	-	(4.487	+	1.771	+	0.00099999999999945)
=	-1.861

	Working Capital		(Q: Dec. 2019 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.521	+	1.942	+	0.36)	-	(2.469	+	1.781	+	0)
=	-1.427

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2019) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Isodiol International's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2019 )
	=	-68.861	/	0.000
	=	%

Isodiol International EBIT Related Terms

Thank you for viewing the detailed overview of Isodiol International's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Isodiol International (Isodiol International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Isodiol International Inc (OTCPK:ISOLF) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Granville Street, Suite 2710, Vancouver, BC, CAN, V6C 1S4

Website

https://www.isodiol.com

Isodiol International Inc is a manufacturer and developer of phytoceutical consumer products using pharmaceutical and nutraceutical grade phytochemical compounds. It generates revenue from the sale of nutritional health products derived from hemp. Geographically, it derives a majority of revenue from the United States and also has a presence in Canada. Its product categories include Tinctures; Capsules; Topicals; Vape; Oral Spray; Skincare; and others.